Latest Headlines

  1. Citizen Health Joins Forces With UCB To Accelerate Drug Development Across Epilepsy And Rare Diseases 12/2/2025

    Citizen Health today announced a new strategic partnership with UCB, a global biopharmaceutical leader in neurological and autoimmune research and development. The multi-year collaboration launches with a focus on epilepsy and five rare disease indications.

  2. Curi Bio Secures $10M Series B To Scale Human-Relevant Preclinical Platforms And Advanced Data Analysis For Drug Discovery 12/2/2025

    Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10M Series B financing round.

  3. Peapod Bio Inc. And Enamine Ltd. Announce Strategic Collaboration 12/2/2025

    Peapod Bio Inc., a leader in innovative assay development and high-throughput screening (HTS) solutions, today announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries.

  4. Latus Bio Announces IND Clearance Of LTS-101 For CLN2 Disease And Receipt Of Fast Track, Orphan Drug, And Rare Pediatric Disease Designations 12/2/2025

    Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announces clearance by the U.S. Food and Drug Administration (FDA) of the Company’s Investigational New Drug (IND) application for LTS-101 - a gene therapy candidate that’s intended to treat the CNS manifestations of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.

  5. LENZ Therapeutics Announces MFDS Submission Of New Drug Application For LNZ100 (VIZZ™) In South Korea For The Treatment Of Presbyopia 12/1/2025

    LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for the treatment of presbyopia in adults in South Korea.

  6. Join Insilico Medicine At NeurIPS 2025: Unveiling Generative AI Breakthroughs Revolutionizing Drug Discovery And Development 12/1/2025

    Insilico Medicine (“Insilico”), a clinical-stage, generative AI-driven drug discovery company, today announced its participation in NeurIPS 2025, to be held in San Diego, USA, from December 2–7, 2025.

  7. US FDA Accepts Wockhardt's New Drug Application For Breakthrough Antibiotic Zaynich 12/1/2025

    Wockhardt Ltd. today announced that the United States Food and Drug Administration (US FDA) has formally accepted the New Drug Application (NDA) for its novel, first-in-class antibiotic Zaynich.

  8. Eisai Submits New Drug Application For Subcutaneous Formulation Of 'LEQEMBI®' For The Treatment Of Early Alzheimer's Disease In Japan 11/27/2025

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI®” (brand name, generic name: lecanemab) seeking approval for a subcutaneous formulation (subcutaneous autoinjector: SC-AI) as a new route of administration to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA).

  9. New Treatment For Acute Myeloid Leukemia 11/25/2025

    Biomedical research that began at the School of Medicine has yielded a much-needed new treatment for patients with the deadliest blood cancer, acute myeloid leukemia.

  10. Drug Discovery Center Integrates AI For Big Impact 11/24/2025

    The UNC Eshelman School of Pharmacy is home to a scientific force driving the future of translational medicine — the Center for Integrative Chemical Biology and Drug Discovery. This center seamlessly blends chemistry, biology and computational science to discover new therapeutic agents and targets.